Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 286-304-6 | CAS number: 85204-10-0
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics, other
- Type of information:
- other: expert statement
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Well documented expert statement based on a series of physicochemical and toxicology studies with WS400402.
Data source
Reference
- Reference Type:
- other: expert statement
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
- Objective of study:
- absorption
- Principles of method if other than guideline:
- Expert statement based on a series of physicochemical and toxicology studies with WS400402.
Test material
- Details on test material:
- - Name of test material: WS400402 or formulation of it
Further details on the test material used in the experimental studies referred to are presented in the respective endpoint study records.
Constituent 1
Results and discussion
Applicant's summary and conclusion
- Executive summary:
No specific study was performed on the absorption, distribution, metabolism, excretion (ADME) of this substance (WS400402), but data are currently available fromin vivoandin vitrotoxicology studies.
The test material, WS400402, is a complex mixture of components; their molecular weights range from 173 to 426 Da. The substance is well water soluble (456 g/L) and accordingly has low lipophilicity (Log10Pow< 1).
After oral administration WS400402 or components of this complex mixture are rapidly absorbed and systemically distributed leading to death after a single oral dose of 2000 mg/kg body weight in rats.
Systemic availability of WS400402 after dermal application is expected to be low based on its hydrophilicity. However, in view of the sensitization response attained in a Local Lymph Node Assay (LLNA) in mice at non-irritating test concentrations of WS400402 some dermal absorption must have occurred. This may have been only a small fraction of the administered test material.
Availability of WS400402 under a vapour state is unlikely, because of its low vapour pressure (3 x 10-4Pa at 25°C) and because it is a highly viscous liquid limiting its availability as an inhalable aerosol.
WS400402 or components of this complex mixture are rapidly absorbed and systemically distributed as was observed from effects in acute and repeated dose oral toxicity studies. There is no information on metabolism of WS400402.
There is no indication in the available study results regarding the excretion of WS400402 or components thereof.
Bioaccumulation of WS400402 is very unlikely based on the high hydrophilicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
